Everolimus for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Authors

Hani M. Babiker
Michael Karass, New York Medical College
Alejandro Recio-Boiles
Sreenivasa R. Chandana
Ali McBride
Daruka Mahadevan

DOI

10.1080/13543784.2019.1632289

Journal Title

Expert Opinion on Investigational Drugs

First Page

583

Last Page

592

Document Type

Article

Publication Date

July 2019

Department

Medicine

Disciplines

Medicine and Health Sciences

Abstract

Introduction: PDAC is a lethal malignancy with a clear unmet need; almost all patients fail 1(st), 2(nd), and 3(rd) line multi-agent cytotoxic chemotherapy. The mammalian target of rapamycin (mTOR) has been identified as a key signaling node enhancing tumor survival and drug resistance in PDAC; hence, it is considered a promising therapeutic target. Areas covered: We comprehensively reviewed the evidence from preclinical and phase I and II clinical trials, based on the authors'clinical experience and a PubMed, Cochrane library, Embase, and Google Scholar search everolimus + pancreatic cancer. Expert opinion: Everolimus has not demonstrated efficacy in PDAC; however, an mTOR inhibitor in combination with stroma-targeted therapies may be a promising area to explore in clinical trials.

Recommended Citation

Babiker, H., Karass, M., Recio-Boiles, A., Chandana, S., McBride, A., & Mahadevan, D. (2019). Everolimus for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma (PDAC). Expert Opinion on Investigational Drugs, 28 (7), 583-592. https://doi.org/10.1080/13543784.2019.1632289